Group 1 - The company has approved a share repurchase plan at the 2024 annual shareholders' meeting, with a total repurchase fund of no less than RMB 50 million and no more than RMB 100 million, at a maximum price of RMB 6.95 per share [1] - The repurchase period is set for a maximum of 6 months from the date of approval, with funds sourced from the company's own and raised funds [1] - As of October 30, 2025, the company has repurchased 8,000,000 shares, accounting for 1.14% of the total share capital, with a total payment of RMB 52,151,912, at a maximum price of RMB 6.65 and a minimum price of RMB 6.30 per share [1] Group 2 - The company will adhere to relevant regulations during the repurchase period and will make repurchase decisions based on market conditions, ensuring timely information disclosure regarding the progress of the share repurchase [2]

Group 1 - The core point of the article is that Yabao Pharmaceutical (600351) announced a share buyback program, having repurchased a total of 8,000,000 shares, which represents 1.14% of the company's total share capital as of October 30, 2025 [1]

Core Viewpoint - Yabao Pharmaceutical (600351.SH) has repurchased a total of 8 million shares, representing 1.14% of the company's total share capital, with a total expenditure of RMB 52.15 million as of October 30, 2025 [1] Summary by Relevant Sections - **Share Repurchase Details** - The company has conducted a share repurchase through centralized bidding [1] - The highest transaction price was RMB 6.65 per share, while the lowest was RMB 6.30 per share [1] - The total amount paid for the repurchase, excluding transaction fees, is RMB 52.15 million [1]

Core Viewpoint - Yabao Pharmaceutical (600351.SH) has repurchased a total of 8 million shares, representing 1.14% of the company's total share capital, with a total expenditure of RMB 52.15 million as of October 30, 2025 [1] Summary by Category - **Share Repurchase Details** - The company has conducted share repurchases through centralized bidding [1] - The highest transaction price for the repurchased shares was RMB 6.65 per share, while the lowest was RMB 6.30 per share [1] - The total amount paid for the repurchase, excluding transaction fees, was RMB 52.15 million [1]

证券代码：600351 证券简称：亚宝药业 公告编号：2025-040 亚宝药业集团股份有限公司 关于回购股份比例达到 1%暨回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/4/26，由董事会提议 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 月 2025 5 16 11 | 日~2025 | 年 | 14 | 日 | | 预计回购金额 | 0.5亿元~1亿元 | | | | | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | 累计已回购股数 | □为维护公司价值及股东权益 8,000,000股 | | | | | | 累计已回购股数占总股本比例 | 1.14% | | | | | | 累计已回购金额 | 52,151,912.00元 | | | | | | 实际回购价格区间 | 6.30元/股~6.65元/股 | ...

Core Viewpoint - Yabao Pharmaceutical (600351.SH) reported its Q3 2025 results, highlighting a decrease in institutional ownership and changes in public fund holdings [1] Group 1: Institutional Investors - As of October 24, 2025, six institutional investors disclosed holdings in Yabao Pharmaceutical, totaling 144 million shares, which represents 20.63% of the company's total equity [1] - The institutional ownership decreased by 3.27 percentage points compared to the previous quarter [1] Group 2: Public Funds - One public fund, Huatai-PineBridge CSI Traditional Chinese Medicine ETF, increased its holdings by 0.16% compared to the last period [1] - A total of 91 public funds did not disclose their holdings this quarter, including various ETFs and mixed funds [1]

Core Points - The company guarantees the authenticity, accuracy, and completeness of the quarterly report, and assumes legal responsibility for any false records or misleading statements [2][8][17] Financial Data - The third-quarter financial statements are unaudited, covering the period from the beginning to the end of the quarter [3][8] - The report includes significant non-recurring gains and losses, but specific amounts are not detailed in the provided documents [4] Shareholder Information - As of the end of the reporting period, the company has a total of 700,000,046 shares, with 6,000,000 shares (0.86%) held in a repurchase account [6] Board Meeting Resolutions - The company's board of directors approved the third-quarter report with unanimous support [8][11] - The board also approved revisions to the company's information disclosure system and management systems for shares held by directors and senior management [11][12][14]

Core Viewpoint - Yabao Pharmaceutical reported a decline in both revenue and net profit for the first three quarters of 2025, indicating a downturn in performance compared to previous years [1][2]. Financial Performance - For the first three quarters of 2025, Yabao Pharmaceutical achieved revenue of 1.709 billion yuan, a year-on-year decrease of 19.46% [1]. - The net profit attributable to shareholders was 215 million yuan, down 8.44% year-on-year [1]. - The third quarter revenue was 569 million yuan, reflecting a 16.01% decline compared to the same period last year [1]. - The net profit for the third quarter was approximately 40.7 million yuan, a significant drop of 26.22% year-on-year [1]. Product Performance - Sales of the flagship product, Dinggui Er Qi贴, decreased by 10.60% to 85.83 million patches, equating to a loss of approximately 10.18 million patches compared to 2023 [2]. - The decline in revenue for the first half of the year was attributed to reduced income from various products, including 消肿止痛贴 and 盐酸倍他司汀注射液 [2]. R&D Developments - The significant drop in total profit for the third quarter was primarily due to the termination of the SY-009 research and development project, which led to asset impairment provisions [2]. - SY-009, a sodium-glucose co-transporter 1 inhibitor intended for type 2 diabetes treatment, did not meet its primary efficacy endpoint in phase II clinical trials, leading to uncertainty in further development [3]. - As of the announcement date, the investment in SY-009's R&D had reached approximately 87.87 million yuan [3].

Core Viewpoint - The company reported a significant decline in revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company achieved a revenue of 1.709 billion yuan, representing a year-on-year decrease of 19.46% [1] - The net profit attributable to shareholders was 215 million yuan, down 8.44% year-on-year [1] - The non-recurring net profit was 197 million yuan, reflecting a decline of 9.03% compared to the previous year [1] - The basic earnings per share stood at 0.3066 yuan [1]

亚宝药业集团股份有限公司 董事及高级管理人员离职管理制度 第一章 总则 第一条 为规范亚宝药业集团股份有限公司（以下简称"公司"）董事及高 级管理人员离职管理事宜，保障公司治理结构的连续性和稳定性，维护公司及全 体股东的合法权益，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《上市公司章程指引》《上市公司治理准则》及《亚宝药业集团股份有限公司章 程》（以下简称"公司章程")的规定，制定本制度。 第二条 本制度适用于公司董事（含独立董事）及高级管理人员因任期届满 未连任、辞任、解任及其他导致董事及高级管理人员实际离职等情形。 第二章 离职情形与生效条件 第三条 董事任期3年，任期届满可以连选连任，但独立董事连任时间不得超 过六年。董事任期届满未获连任的，自换届的股东会决议通过之日自动离职。股 东会可以决议解任董事，决议作出之日解任生效。无正当理由，在任期届满前解 任董事的，董事可以要求公司予以赔偿。 第四条 如存在以下情形的，在改选出的董事就任前，原董事仍应当依照法 律、行政法规、部门规章和公司章程规定，履行董事职务，但存在相关法规另有 规定的除外： （一）董事任期届满未及时改选，或者董事在任期内辞 ...